statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	696
SG - Singapore	169
CN - Cina	109
BR - Brasile	85
DE - Germania	68
VN - Vietnam	67
IT - Italia	48
HK - Hong Kong	34
BD - Bangladesh	26
FI - Finlandia	21
FR - Francia	18
GB - Regno Unito	18
SE - Svezia	17
IN - India	16
RU - Federazione Russa	13
CA - Canada	11
AR - Argentina	10
JP - Giappone	9
ZA - Sudafrica	9
PL - Polonia	7
UA - Ucraina	7
BE - Belgio	6
NL - Olanda	6
TR - Turchia	6
AT - Austria	5
IQ - Iraq	5
MX - Messico	5
CZ - Repubblica Ceca	4
ES - Italia	4
OM - Oman	4
ID - Indonesia	3
LT - Lituania	3
MA - Marocco	3
AE - Emirati Arabi Uniti	2
EC - Ecuador	2
GT - Guatemala	2
JM - Giamaica	2
JO - Giordania	2
NI - Nicaragua	2
SA - Arabia Saudita	2
AO - Angola	1
AU - Australia	1
AZ - Azerbaigian	1
CL - Cile	1
CO - Colombia	1
CR - Costa Rica	1
DK - Danimarca	1
DZ - Algeria	1
GE - Georgia	1
HN - Honduras	1
HU - Ungheria	1
IM - Isola di Man	1
KE - Kenya	1
KM - Comore	1
KZ - Kazakistan	1
NP - Nepal	1
PA - Panama	1
PK - Pakistan	1
PS - Palestinian Territory	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
TO - Tonga	1
TT - Trinidad e Tobago	1
VE - Venezuela	1
Totale	1.550

Nome	#
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure	198
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy	183
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection	181
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality	171
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors	166
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI	156
Three-years follow up of raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the ISS-NIA cohort	142
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice	139
Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study.	118
Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virologic failure and drug discontinuation: data from the ICONA Foundation cohort.	108
Totale	1.562

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	5	0	0	0	0	0	0	0	0	0	0	0	5
2021/2022	71	3	6	0	1	8	4	1	2	3	9	1	33
2022/2023	103	11	14	6	11	19	10	10	6	9	0	7	0
2023/2024	60	2	9	3	4	6	11	0	6	2	0	1	16
2024/2025	330	5	2	20	17	34	44	6	9	60	27	54	52
2025/2026	853	108	39	55	119	133	59	106	45	67	56	30	36
Totale													1.562

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara